Preparation and in vitro evaluation of Eudragit microspheres containing acetazolamide

Haznedar, S.; Dortunç, Betül

doi:10.1016/j.ijpharm.2003.09.015

Cited by 186 publications

(104 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Due to their competence to form nanodispersion with smaller particle size, positive surface charge, excellent stability, lack of any irritant effect on the cornea, iris and conjunctiva, Eudragit Ò nanoparticles come forth to be a suitable inert carrier for ophthalmic drug delivery (Haznedar and Dortunc 2004). They are inert polymer resins, insoluble at physiologic pH but have swelling properties.…”

Section: Introductionmentioning

confidence: 99%

In vitro, in vivo and pharmacokinetic assessment of amikacin sulphate laden polymeric nanoparticles meant for controlled ocular drug delivery

et al. 2014

View full text Add to dashboard Cite

The rationale of current exploration was to formulate positively charged amikacin-loaded polymeric nanoparticles providing a controlled release attribute. Amikacin sulphate-loaded nanoparticles were prepared by w/o/w emulsification solvent evaporation approach succeeded by high-pressure homogenization. Two bioadhesive positively charged polymers, Eudragit Ò RS 100 and Eudragit Ò RL 100, were used in the blend, with variable ratios of drug and polymer. The formulations were assessed in terms of particle size and zeta potential. Thermal gravimetric analysis was brought out on the samples of drug, polymer and drug polymer complex. Drug loading and release attributes of the nanoparticles were scrutinized and antimicrobial activity in contrast to Staphylococcus aureus was appraised. Ocular irritation test, in vivo ocular retention study, in vivo release profile (permeation study) and in vivo antibacterial activity of polymeric nanosuspensions were executed. No rupture consequence but a lengthened drug release was contemplated from all formulations. Amikacin sulphate release from the polymeric nanoparticles reflected a better fit with Korsmeyer-Peppas model. In the course of the antibacterial activity of nanoparticles against S. aureus, formulation AE1 displays the most prominent inhibitory effect as compared with marketed formulation of amikacin sulphate.

show abstract

Section: Introductionmentioning

confidence: 99%

In vitro, in vivo and pharmacokinetic assessment of amikacin sulphate laden polymeric nanoparticles meant for controlled ocular drug delivery

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Either an increase or reduction in the size of PLGA NPs has also been observed while increasing the concentration of PVA [16]. In recent studies, the size of PLGA NPs have been observed to be dependent on the viscosity of emulsion during preparation, such that, low viscosity emulsions results to small particles size and high viscosity emulsions result to higher particles size [17] [18].…”

Section: Effect Of Process Parameters On Nps Sizementioning

confidence: 99%

Ciprofloxacin Hydrochloride Encapsulated into PLGA Nanoparticles for Drug Delivery Application: Fractional Factorial Design

Adebileje¹,

Adebileje²,

Aye³

2018

OALib

View full text Add to dashboard Cite

Over several decades, poly (lactic-co-glycolic acid) (PLGA) have been widely used as Micro-and Nano-carriers of therapeutic agents for drug delivery applications. However, encapsulation process of therapeutic agents into PLGA Nanoparticles (NPs) necessitates a defined step to understand the effects and interactions of parameters involved in production process. In pharmaceutics formulations, compared to one factor at a time (OFAT) approach, statistical design of experiments (DOE) supersedes OFAT approach due to limited number of experiments required to investigate effects and interactions of a process parameters. The major objectives of the present study were to: 1) prepare and understand the effect of selected formulation parameters on particles size and drug recovery of PLGA NPs encapsulating Ciprofloxacin Hydrochloride (Cip-HCl) using a fractional factorial design (FFD) as a DOE approach;2) understand the in-vitro release of Cip-HCl from PLGA NPs. Cip-HCl loaded PLGA were prepared by W 1 /O/W 2 double emulsion solvent evaporation (DESE) method using poly-vinyl alcohol as a stabilizer. The Sizes of NPs were within 202 nm to 530 nm and percentage Cip-HCl recovered from dried NPs were within 1.7% w/w to 15.7% w/w. Increasing concentrations of PLGA and Cip-HCl was observed to increase NPs size. Increasing PVA concentration was observed to either reduce or increase NPs size. Increasing PLGA concentration was observed to increase the amount of Cip-HCl recovered. Within 1 -24 hours, optimized formulations shows a controlled release of Cip-HCl from PLGA NPs.

show abstract

“…13,14 The physiochemical properties of core materials like solubility, diffusibility and partition coefficient and of coating materials like variable porosity, thickness and inertness which makes difficult to modeling of drug release. However, based on various studies concerning with the release characteristics, the following considerations can be made-1) Drug release rate from microcapsules follow the zero order kinetic.…”

Section: Mechanism and Kinetics Of Drug Releasementioning

confidence: 99%

Microencapsulation for controlled drug delivery: a comprehensive review

Gupta

Dey

2013

Sunsari Tech. Coll. J.

View full text Add to dashboard Cite

Microencapsulation is described as a process of enclosing micron sized particles of solids or droplets of liquids or gasses in an inert shell, which in turn isolates and protects them from the external environment as well as control the drug release profile. Microencapsulated particle is having diameter between 3 [-] 800µm which differ them from other technologies such as nanotechnology and macroparticle in their morphology and internal structure. This review paper will address the background of microencapsulation technology, commonly used microencapsulation methods with its advantages and disadvantages and its applications in pharmaceutical field. This article also gives an overview on the general aspects and recent advances in drug-loaded microparticles to improve the efficiency of various medical treatments. The review paper will also address about the other factors affecting microencapsulation and its limitation. The article will also discuss about various findings described in the published scientific journals and patent literatures. Based on the existing results and authors' reflection, this review gives rise to reasoning and suggested choices of process parameters and microencapsulation procedure.

show abstract

Preparation and in vitro evaluation of Eudragit microspheres containing acetazolamide

Cited by 186 publications

References 14 publications

In vitro, in vivo and pharmacokinetic assessment of amikacin sulphate laden polymeric nanoparticles meant for controlled ocular drug delivery

In vitro, in vivo and pharmacokinetic assessment of amikacin sulphate laden polymeric nanoparticles meant for controlled ocular drug delivery

Ciprofloxacin Hydrochloride Encapsulated into PLGA Nanoparticles for Drug Delivery Application: Fractional Factorial Design

Microencapsulation for controlled drug delivery: a comprehensive review

Contact Info

Product

Resources

About